IL22 and liver dysplastic nodule: Collectively, we found that IL-22 gene therapy could exert favorable effects on established DN via simultaneously alleviating systemic metabolic syndrome and downregulating renal NLRP3 inflammasome activation (Supplementary Figure 7).